IBU-Octyl-Cytisine, a novel bifunctional compound eliciting anti-inflammatory and cholinergic activity, ameliorates CNS inflammation by inhibition of T-cell activity

International Immunopharmacology

Volumn 7, Issue 9, 2007, Pages 1129-1139

  Nizri, Eran ^a   Irony Tur Sinai, Michal ^a   Lavon, Iris ^b   Meshulam, Haim ^c   Amitai, Gabi ^c   Brenner, Talma ^a  

^a Agnes Ginges Center for Human Neurogenetics   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c IIBR   (Israel)

Author keywords

Alpha 7 nicotinic receptor; Bifunctional compounds; Central nervous system inflammation; Experimental autoimmune encephalomyelitis; Multiple sclerosis; T cell activity

Indexed keywords

IBUPROFEN OCTYLCYTISINE; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL LINEAGE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; FETUS; IMMUNOPATHOGENESIS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSCRIPTION REGULATION;

ALKALOIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZOCINES; CELLS, CULTURED; CHOLINERGIC AGENTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IBUPROFEN; MICE; MICE, INBRED C57BL; NEUROGLIA; PYRIDINIUM COMPOUNDS; QUINOLIZINES; RATS; T-LYMPHOCYTES;

EID: 34447293986     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.03.009     Document Type: Article

References (29)

1. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11 3 (2005) 328-334
2. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3 4 (2002) 291-301
3. Amitai G., Rabinovitz I., Beit-Yanai E., Shohami E., Sod-Moriah G., and Meshulam H. Cholinergic mechanisms: function and dysfunction. Newgen imaging systems (2004) 277-288 Chapter 41
4. Moon C., Ahn M., Wie M.B., Kim H.M., Koh C.S., Hong S.C., et al. Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes. Brain Res 1035 2 (2005) 206-210
5. Sacco S., Agnello D., Sottocorno M., Lozza G., Monopoli A., Villa P., et al. Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats. J Neurochem 71 5 (1998) 2063-2070
6. Scheuren N., Bang H., Munster T., Brune K., and Pahl A. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol 123 4 (1998) 645-652
7. Barnes P.J., and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 15 (1997) 1066-1071
8. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 6921 (2003) 384-388
9. Nizri E., Hamra-Amitay Y., Sicsic C., Lavon I., and Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 50 5 (2006) 540-547
10. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10 11 (2004) 1216-1221
11. Nizri E., Adani R., Meshulam H., Amitai G., and Brenner T. Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments. Neurosci Lett 376 1 (2005) 46-50
12. Astles P.C., Baker S.R., Boot J.R., Broad L.M., Dell C.P., and Keenan M. Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neurol Disord 1 4 (2002) 337-348
13. Sato K.Z., Fujii T., Watanabe Y., Yamada S., Ando T., Kazuko F., et al. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci Lett 266 1 (1999) 17-20
14. Carbonnelle E., Sparatore F., Canu-Boido C., Salvagno C., Baldani-Guerra B., Terstappen G., et al. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur J Pharmacol 471 2 (2003) 85-96
15. Pinto F., Brenner T., Dan P., Krimsky M., and Yedgar S. Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation. Glia 44 3 (2003) 275-282
16. Brenner T., Poradosu E., Soffer D., Sicsic C., Gazit A., and Levitzki A. Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556. Exp Neurol 154 2 (1998) 489-498
17. Singh S.P., Kalra R., Puttfarcken P., Kozak A., Tesfaigzi J., and Sopori M.L. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol Appl Pharmacol 164 1 (2000) 65-72
18. Bagaeva L.V., Williams L.P., and Segal B.M. IL-12 dependent/IFN gamma independent expression of CCR5 by myelin-reactive T cells correlates with encephalitogenicity. Neuroimmunology 137 1-2 (2003) 109-116
19. Glabinski A.R., Bielecki B., O'Bryant S., Selmaj K., and Ransohoff R.M. Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells. J Autoimmun 19 4 (2002) 175-181
20. Irony-Tur-Sinai M., Grigoriadis N., Lourbopoulos A., Pinto-Maaravi F., Abramsky O., and Brenner T. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp Neurol 198 1 (2006) 136-144
21. Murphy K.M., and Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol 2 12 (2002) 933-944
22. Slikkker W., Youdim M., Palmer G.C., Hall E., Williams C., and Trembly B. The future of neuroprotection. Ann N Y Acad Sci 890 (1999) 529-533
23. Drews J. Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov 5 8 (2006) 635-640
24. Kanwar J.R., Kanwar R.K., and Krissansen G.W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 127 Pt 6 (2004) 1313-1331
25. Amitai G., Rabinovitz I., Sod-Moriah G., Brandeis R., and Rachaman E.H.E. Quaternary lipophilic carbamates with blood-brain barrier permeability as potential drugs for the treatment of diseases associated with cholinergic deficiency. In: Doctor B.P., Taylor P., Quin R.L., Rotundo R.L., and Gentry M.K. (Eds). Structure and Function of Choinesterases and Related Proteins (1998), Plenum Press
26. Moon C., Ahn M., Jee Y., Heo S., Kim S., Kim H., et al. Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett 356 2 (2004) 123-126
27. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2 5 (2002) 372-377
28. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., and Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 200 1 (2004) 79-87
29. Nizri E., Irony-Tur-Sinai M., Grigoriadis N., Abramsky O., Amitai G., and Brenner T. Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development. Pharmacology 79 1 (2006) 42-49